Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  mesna
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 33 for your search:
Start Over
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0065, NCI-2012-01779, NCT01169636
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2010-0991, NCI-2011-01123, NCT01371630
T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 14 and over
Sponsor: NCI, Other
Protocol IDs: 2009-0471, 2RO1CA116206-06, NCI-2014-02655, NCT01740557
NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 65
Sponsor: Other
Protocol IDs: 2012-0708, NCI-2013-02183, RP110553 05-07-04832, P01 - 5P01, NCT01904136
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALDOXORUBICIN-P1/2-STS-03, NCT02235701
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: 150067, 15-C-0067, NCT02356159
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WG2014035, NCT02408042
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 64
Sponsor: Other
Protocol IDs: 20080803, SCCC-2008043, EPROST-20080803, NCT00878254
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2009-0266, NCI-2011-03144, NCT01010217
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0598, NCI-2011-00861, NCT01319981
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: UCBT01, NCI-2011-03700, NCT01328496
Stem Cell Collection With Ofatumumab
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2009-0796, NCI-2011-01068, NCT01329900
IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LMTG 11-02, NCT01333605
Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2010-0708, NCI-2011-01061, NCT01363128
Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0030, NCI-2011-02941, NCT01424982
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PLRG8 (OMB114361), 2010-023568-42, NCT01481272
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
Phase: Phase II
Type: Treatment
Status: Active
Age: 40 and under
Sponsor: Other
Protocol IDs: GEIS-21, 2009-016027-62, NCT01696669
Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: PUMCH-S464, NCT01749072
KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: HAPNK1, NCI-2013-00609, NCT01807611
Therapy for Children With Advanced Stage Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 19
Sponsor: Other
Protocol IDs: NB2012, NCI-2013-00034, NCT01857934
Ph II Cabazitaxel/Ifosfamide DD Liposarcoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: EORTC-1202, 2012-003672-39, cabazL06470, NCT01913652
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0367, NCI-2014-01356, NCT02106988
Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 6 months to 25 years
Sponsor: Other
Protocol IDs: J13161, NA_00091665, NCT02120157
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 73 and under
Sponsor: Other
Protocol IDs: J1424, IRB00031590, NCT02224872
Start Over